Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas

Human Reproduction

Volumn 19, Issue 6, 2004, Pages 1308-1314

  Palomba, Stefano ^a,d   Orio Jr , Francesco ^b   Russo, Tiziana ^a   Falbo, Angela ^a   Cascella, Teresa ^b   Doldo, Patrizia ^a   Nappi, Carmine ^b   Lombardi, Gaetano ^b   Mastrantonio, Pasquale ^c   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d University of Messina ^*  (Italy)

Author keywords

Bone loss; GnRH a; Leiomyomas Metabolism Raloxifene

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CREATININE; DEOXYPYRIDINOLINE; ESTROGEN; GESTAGEN; GLUCOSE; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEUPRORELIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; RALOXIFENE; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LONG TERM CARE; MENOPAUSAL SYNDROME; OSTEOLYSIS; OSTEOPENIA; PATIENT COMPLIANCE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME; UTERUS BLEEDING; UTERUS MYOMA;

EID: 3042683626     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh296     Document Type: Article

References (45)

1. Al-Omari WR, Nassir UN and Sulaiman WR (1999) Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist. Int J Obstet Gynecol 66,191-192.
2. Al-Omari WR, Nassir UN and Izzat B (2001) Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy. Int J Obstet Gynecol 74,61-62.
3. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffmann RF and Bensch WR (1994) Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93,63-69.
4. Broekmans FJ, Hompes PGA, Heitbrink MA, Netelenbos CC, Roos JC, Falke TM and Schoemaker J (1996a) Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy. Am J Obstet Gynecol 175,1208-1216.
5. Broekmans FJ, Heitbrink MA, Hompes PG, Schoute E, Falke T and Schoemaker J (1996b) Quantitative MRI of uterine leiomyomas, during triptorelin treatment: reproducibility of volume assessment and predictability of treatment response. Magn Reson Imaging 14,1127-1135.
6. Bryant HU, Glasebrook AL, Yang NN and Sato M (1996) A pharmacological review of raloxifene. J Bone Miner Metab 14,1-9.
7. Carr BR, Marshburn PB and Weatherall PT (1993) An evaluation of the effect of gonadotropin-reteasing hormone analog and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double-blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 76,1217-1223.
8. Cheung T-H, Lo KW-K, Lam CW-K, Lau W-C and Lam PK-W (2000) A crossover study of triptolin and leuprolide acetate. Fertil Steril 74,299-305.
9. Clemett D and Spencer CM (2000) Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60,379-411.
10. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G, The Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23,524-528.
11. Cucinelli F, Soranna L, Romualdi D, Muzj G, Mancuso S and Lanzone A (2002) The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study. J Clin Endocrinol Metab 87,4186-4192.
12. DeLeo V, la Marca A, Morgante G, Lanzetta D, Setacci,C and Petraglia F (2001) Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 184,350-353.
13. Efstathiadou Z and Tsatsoulis A (2001) Long-term remission of ovarian hyperandrogenisin after short-term treatment with a gonadotropin-releasing hormone agonist. Fertil Steril 75,59-62.
14. Friedewald WT, Levy RI and Fredrickson DS (1972) Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge. Clin Chem 18, 499-502.
15. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R and Leboff M (1993) A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin 'add-back' regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76,1439-1445.
16. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS and Leboff M (1994) Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oetrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 9,1618-1625.
17. Fuchs-Young R, Howe S, Hale L, Miles R and Walker C (1996) Inhibition of estrogen stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 17,151-159.
18. Gerhard I, Schindler AE, Buhler K, Winkler U, Memen K, Mancarella D, Hoffmann G, Schussler B, Kimmig R and Kranzfelder D (1992) Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther 14 (Suppl A) 3-16.
19. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW and Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95,95-103.
20. Jirecek S, Lee A, Pavo I, Crans G, Eppel W and Wenzi R (2004) Raloxitene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 81,132-136.
21. Matta WH, Shaw RW, Hesp R and Evans R (1988) Reversible trabecular bone density loss following hypo-oestrogenism with GnRH analogue buserelin in premenopausal women. Clin Endocrinol 29,45-51.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28,412-419.
23. Modelska K and Cummings S (2002) Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87,16-23.
24. Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR and Jaffrey RB (1986) Dose-dependent inhibition of pituitary-ovarian function during administration of gonadotropin-releasing hormone agonist analog (nafarelin). J Clin Endocrinol Metab 63,1334-1341.
25. Nakayama H, Yano T, Sagara Y, Kikuchi A, Ando K, Wang Y, Watanabe M, Matsumi H, Osuga Y, Momoeda M and Taketani Y (1999) Estriol add-back therapy in the long acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Gynecol Endocrinol 13,382-389.
26. Palomba S, Affinito P, Tommaselli GA and Nappi C (1998) A clinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 70,111-118.
27. Palomba S, Affinito P, Di Carlo C, Bifulco G and Nappi C (1999) Effects of long-term administration of tibolone plus GnRH-a in the treatment of uterine leiomyomata on effectiveness, vasomotor symptoms, bone mass and lipid profile. Fertil Steril 72,889-895.
28. Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F and Nappi C (2001a) Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 76,38-43.
29. Palomba S, Pellicano M, Affinito P, Di Carlo C, Zullo F and Nappi C (2001b) Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil Steril 75,429-433.
30. Palomba S, Morelli M, Di Carlo C, Noia R, Pellicano M and Zullo F (2002a) Bone metabolism in postmenopausal women who have been treated with a gonadotropin-releasing hormone agonist and tibolone. Fertil Steril 78,63-68.
31. Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Zupi E, Lombardi G, Nappi, C, Benedetti Panici PG and Zullo F (2002b) Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87,3303-3308.
32. Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Nappi C, Mastrantonio P, Lombardi G, Colao A and Zullo F (2002c) Raloxifene administration in women treated with gonadotropin releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 87,4476-4481.
33. Palomba S, Russo T, Orio F Jr, Tauchmananovà L., Zupi E, Benedetti Panici PG, Nappi C, Colao A, Lombardi G and Zullo F (2002d) Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 17,3213-3219.
34. Palomba S, Russo T, Orio F Jr, Sammartino A, Sbano FM, Nappi C, Colao A, Lombardi G and Zullo F (2004) Lipid, glucose, and homocysteine metabolism in women treated with a gonadotropin-releasing hormone agonist with or without raloxifene. Hum Reprod 19,415-421.
35. Pickersgill A (1998) GnRH agonists and add-back therapy: is there a perfect combination ? Br J Obstet Gynecol 105,475-485.
36. Pierce SJ, Gazvani MR and Farquharson RG (2000) Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 74,964-968.
37. Porter KB, Tsibris JC, Porter GW, Fuchs-Young R, Nicosia SV and O'Brien WF (1998) Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 179,1283-1287.
38. Revilla R, Revilla M, Hernandez ER, Villa LF, Valera L and Rico H (1995) Evidence that the loss of bone mass induced by GnRH agonist is not totally recovered. Maturitas 22,145-150.
39. Sherwin BB and Tulandi T (1996) 'Add-back' estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81,2545-2549.
40. Somekawa Y, Chiguchi M, Ishibashi T, Wakana K and Aso T (2001) Efficacy of ipriflavone in preventing adverse effects of leuprolide. J Clin Endocrinol Metab 86,3202-3206.
41. Surrey ES (1995) Steroidal and nonsteroidal 'add-back' therapy: extending safety and efficacy of gonadotropin-releasing hormone agonist in the gynecologic patient. Fertil Steril 64,673-685.
42. Surrey ES (1999) Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril 71,420-424.
43. Taga M and Minaguchi H (1996) Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75,162-165.
44. Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI and Fuchs-Young R (2000) Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Invest 7,249-256.
45. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA and Anderson PW (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85,214-218.